“insomniaare”的搜索结果，显示 601-610 项，共有 2611 项

1. 神经科- 临床试验- 妙佑医疗国际

   To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately ...

2. 神经科- 临床试验- 妙佑医疗国际

   To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately ...

3. 神经科- 临床试验- 妙佑医疗国际

   To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately ...

4. 神经科- 临床试验- 妙佑医疗国际

   Jacksonville, Fla. C3FIT's overall goal is to assess if patient outcomes are improved when the Comprehensive and Primary Stroke Center (CSC/PSC) system is ...

5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

   PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves ...

6. 神经科- 临床试验- 妙佑医疗国际

   To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately ...

7. 神经科- 临床试验- 妙佑医疗国际

   To determine if patients who are diagnosed with the revised 2015 IPND criteria, in particular those who do not satisfy previous criteria, are ultimately ...

8. 神经科- 临床试验- 妙佑医疗国际

   C3FIT's overall goal is to assess if patient outcomes are improved when the Comprehensive and Primary Stroke Center (CSC/PSC) system is supplemented with an ...

9. 神经科- 临床试验- 妙佑医疗国际

   The purpose of this study is to determine whether treatment of obstructive sleep apnea (OSA) with positive airway pressure starting shortly after acute ischemic ...

10. 神经科- 临床试验- 妙佑医疗国际

    The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with ...